Table 4.
Hematological value of male rats treated with GlucoMedix® at 28 days
| Group/dose (mg/kg) | HCT (%) | HGB (g/dl) | WBC Differential Counting | RBC x106cell/uL | WBC x103cell/uL | |||
|---|---|---|---|---|---|---|---|---|
| NEU | MON | EOS | LYM | |||||
| (%) | (%) | (%) | (%) | |||||
| 250 | 41.46 ± 0.80 | 13.90 ± 0.32 | 59.00 ± 2.92 | 4.00 ± 1.00 | 2.40 ± 0.55 | 32.80 ± 3.11 | 4.64 ± 0.38 | 7.16 ± 0.34 |
| 1000 | 43.44 ± 0.88 * | 14.76 ± 0.52 | 59.60 ± 3.21 | 3.80 ± 0.84 | 1.60 ± 0.55 | 35.20 ± 2.86 | 4.96 ± 0.18* | 6.98 ± 0.16 |
| 2000 | 44.54 ± 0.75 * | 15.82 ± 0.61* | 59.40 ± 2.88 | 4.20 ± 0.84 | 1.60 ± 0.89 | 35.00 ± 3.32 | 5.04 ± 0.21* | 7.36 ± 0.29 |
| Control | 40.94 ± 0.60 | 13.84 ± 0.50 | 59.20 ± 2.77 | 3.40 ± 0.55 | 1.80 ± 0.45 | 35.60 ± 2.07 | 4.06 ± 0.26 | 6.94 ± 0.21 |
Values are expressed as mean ± SD. n = 5. Parameters include HCT Hematocrit, HGB Hemoglobin, NEU Neutrophils, MON Monocytes, EOS Eosinophils, LYM Lymphocytes, RBC Red blood cells, and WBC White blood cells. * p < 0.05 compared to control group